A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf.
OP0086 The fully human anti-tnf monoclonal antibody, adalimumab (d2e7), dose ranging study: the 24-week clinical results in patients with active ra on methotrexate therapy (the armada trial)
2001
Speaker abstracts 2001
unpublished
Preserved Fulltext
OP0085 Table 1 Mean ACR-N and change in TSS at weeks 30, 54, and 102 in ACR20 non-responders at week 30 Placebo 3 mg/ kg q 8 wks
doi:10.1136/annrheumdis-2001.1216
fatcat:2lju3bgl5zcjjfnfh2xoxjyy5u